Xinxiang Tuoxin Pharmaceutical Co.Ltd. (301089) - Net Assets
Based on the latest financial reports, Xinxiang Tuoxin Pharmaceutical Co.Ltd. (301089) has net assets worth CN¥1.47 Billion CNY (≈ $215.82 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.65 Billion ≈ $241.59 Million USD) and total liabilities (CN¥176.07 Million ≈ $25.76 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See Xinxiang Tuoxin Pharmaceutical Co.Ltd. balance sheet quality to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.47 Billion |
| % of Total Assets | 89.34% |
| Annual Growth Rate | 25.32% |
| 5-Year Change | 35.25% |
| 10-Year Change | N/A |
| Growth Volatility | 43.28 |
Xinxiang Tuoxin Pharmaceutical Co.Ltd. - Net Assets Trend (2019–2025)
This chart illustrates how Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Xinxiang Tuoxin Pharmaceutical Co.Ltd. stock valuation.
Annual Net Assets for Xinxiang Tuoxin Pharmaceutical Co.Ltd. (2019–2025)
The table below shows the annual net assets of Xinxiang Tuoxin Pharmaceutical Co.Ltd. from 2019 to 2025. Also explore Xinxiang Tuoxin Pharmaceutical Co.Ltd. (301089) equity growth momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.48 Billion ≈ $217.18 Million |
-4.40% |
| 2024-12-31 | CN¥1.55 Billion ≈ $227.18 Million |
-3.17% |
| 2023-12-31 | CN¥1.60 Billion ≈ $234.61 Million |
+16.49% |
| 2022-12-31 | CN¥1.38 Billion ≈ $201.41 Million |
+25.43% |
| 2021-12-31 | CN¥1.10 Billion ≈ $160.58 Million |
+123.55% |
| 2020-12-31 | CN¥490.87 Million ≈ $71.83 Million |
+28.13% |
| 2019-12-31 | CN¥383.11 Million ≈ $56.06 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 240.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥667.77 Million | 44.99% |
| Other Components | CN¥816.40 Million | 55.01% |
| Total Equity | CN¥1.48 Billion | 100.00% |
Xinxiang Tuoxin Pharmaceutical Co.Ltd. Competitors by Market Cap
The table below lists competitors of Xinxiang Tuoxin Pharmaceutical Co.Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zhejiang Yueling Co Ltd
SHE:002725
|
$414.32 Million |
|
Fujian SBS Zipper Science Tech
SHE:002098
|
$414.38 Million |
|
RattanIndia Power Limited
NSE:RTNPOWER
|
$414.66 Million |
|
Editas Medicine Inc
NASDAQ:EDIT
|
$414.67 Million |
|
PetroChina Jinhong Energy Investment Co Ltd
SHE:000669
|
$414.19 Million |
|
Malteries Franco-Belges Société Anonyme
PA:MALT
|
$414.15 Million |
|
Clenergy Xiamen Technology Co Ltd
SHG:603628
|
$414.12 Million |
|
Kolte - Patil Developers Limited
NSE:KOLTEPATIL
|
$414.07 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,552,520,060 to 1,484,176,685, a change of -68,343,375 (-4.4%).
- Net loss of 69,661,028 reduced equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-69.66 Million | -4.69% |
| Other Changes | CN¥1.32 Million | +0.09% |
| Total Change | CN¥- | -4.40% |
Book Value vs Market Value Analysis
This analysis compares Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.91x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 5.52x to 1.91x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | CN¥4.05 | CN¥22.37 | x |
| 2020-12-31 | CN¥5.19 | CN¥22.37 | x |
| 2021-12-31 | CN¥8.71 | CN¥22.37 | x |
| 2022-12-31 | CN¥10.92 | CN¥22.37 | x |
| 2023-12-31 | CN¥12.67 | CN¥22.37 | x |
| 2024-12-31 | CN¥12.27 | CN¥22.37 | x |
| 2025-12-31 | CN¥11.73 | CN¥22.37 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Xinxiang Tuoxin Pharmaceutical Co.Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -4.69%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -18.41%
- • Asset Turnover: 0.23x
- • Equity Multiplier: 1.12x
- Recent ROE (-4.69%) is below the historical average (10.71%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 15.99% | 15.87% | 0.52x | 1.93x | CN¥22.94 Million |
| 2020 | 22.98% | 21.37% | 0.56x | 1.93x | CN¥63.71 Million |
| 2021 | 5.99% | 13.08% | 0.36x | 1.27x | CN¥-44.02 Million |
| 2022 | 20.82% | 36.51% | 0.43x | 1.34x | CN¥148.90 Million |
| 2023 | 15.16% | 29.09% | 0.45x | 1.15x | CN¥82.75 Million |
| 2024 | -1.28% | -4.72% | 0.24x | 1.13x | CN¥-175.14 Million |
| 2025 | -4.69% | -18.41% | 0.23x | 1.12x | CN¥-218.08 Million |
Industry Comparison
This section compares Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $8,448,219,723
- Average return on equity (ROE) among peers: 10.70%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Xinxiang Tuoxin Pharmaceutical Co.Ltd. (301089) | CN¥1.47 Billion | 15.99% | 0.12x | $414.24 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $2.14 Billion | 22.15% | 4.96x | $585.22 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.15 Billion | 3.98% | 1.16x | $407.31 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $897.61 Million | 10.79% | 0.14x | $4.27 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $14.94 Billion | 12.78% | 0.66x | $2.26 Billion |
| Wedge Industrial Co Ltd (000534) | $552.92 Million | 0.39% | 0.01x | $1.78 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $38.10 Billion | 10.98% | 0.30x | $13.33 Billion |
| Hainan Haiyao Co Ltd (000566) | $5.63 Billion | 2.92% | 0.71x | $875.19 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $141.91 Million | 11.01% | 0.32x | $311.17 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $2.05 Billion | 23.18% | 1.96x | $973.03 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $18.87 Billion | 8.83% | 0.08x | $3.07 Billion |
About Xinxiang Tuoxin Pharmaceutical Co.Ltd.
Tuoxin Pharmaceutical Group Co.,Ltd. engages in the research and development, production and sales of nucleoside (acid) APIs and pharmaceutical intermediates in China. It offers nucleoside (acid) products, such as pyrimidine series, purine series, and nucleotide series; nucleoside series, including citicoline sodium, ribavirin, inosine, acyclovir, cytosine, 5-fluorocytosine, cytidine, uridine; an… Read more